Back to Search
Start Over
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
- Source :
- Clin Cancer Res
- Publication Year :
- 2021
-
Abstract
- Purpose: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cells (CART-BCMA) are a promising treatment for relapsed/refractory multiple myeloma (r/rMM). We evaluated the safety and feasibility of bridging radiation (RT) in subjects treated on a phase I trial of CART-BCMA. Experimental Design: Twenty-five r/rMM subjects were treated in three cohorts with two doses of CART-BCMA cells ± cyclophosphamide. We retrospectively analyzed toxicity, response, and CART manufacturing data based on RT receipt. Results: Thirteen subjects received no RT Conclusions: Bridging-RT appeared safe and feasible with CART-BCMA therapy in our r/rMM patients, though larger future studies are needed to draw definitive conclusions.
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Future studies
Cyclophosphamide
Immunotherapy, Adoptive
Article
Antigen
immune system diseases
Internal medicine
medicine
Humans
B-Cell Maturation Antigen
Multiple myeloma
Retrospective Studies
Receptors, Chimeric Antigen
business.industry
Refractory Multiple Myeloma
medicine.disease
Chimeric antigen receptor
Toxicity
CAR T-cell therapy
business
Multiple Myeloma
medicine.drug
Subjects
Details
- ISSN :
- 15573265
- Volume :
- 27
- Issue :
- 23
- Database :
- OpenAIRE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Accession number :
- edsair.doi.dedup.....c70adc439970f07a094cfda50555f9da